From: Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Gefitinib | Erlotinib | |||
---|---|---|---|---|
No | % | No | % | |
TOTAL | 115 | 45 | ||
Gender | ||||
Female | 55 | 48 | 30 | 67 |
Male | 60 | 52 | 15 | 33 |
Age | ||||
Avg. age | 66.53 | 66.76 | ||
Range | 45-86 | 35-82 | ||
Smoking history | ||||
Smokers | 109 | 95 | 39 | 87 |
Non-smokers | 5 | 1 | 4 | 9 |
Unknown | 1 | 1 | 2 | 4 |
Avg. pack-years | 43.6 | 42.2 | ||
Histology | ||||
Adenocarcinoma | 54 | 47 | 15 | 33 |
Squamous | 27 | 23 | 9 | 20 |
Bronchioalveolar | 8 | 6 | 2 | 4 |
Large cell | 6 | 5 | 0 | 0 |
Mixed | 2 | 2 | 0 | 0 |
NSC not further specified | 17 | 15 | 20 | 44 |
Avg. ECOG | 1.37 | 1.37 | ||
Avg. previous lines of chemo | 1.26 | 1.13 |